111 patents
Page 3 of 6
Utility
Methods for Treating Intracranial Hemorrhage and Assessing Efficacy
28 Apr 22
The present disclosure relates to compositions and methods useful for assessing the efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor.
Patrick Yue
Filed: 7 Feb 20
Utility
ANTI-ALK2 Antibodies and Uses Thereof
31 Mar 22
Provided herein are antibodies that bind to activin receptor—like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth.
Jeffrey William Hunter, Julian Chandler, Keith Bouchard, Andre Marozsan, Patricia Bento, Anjli Kukreja
Filed: 5 Dec 19
Utility
Process for Making Recombinant Antidote to Factor Xa Inhibitor
31 Mar 22
Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote.
Genmin Lu, Pamela B. Conley, Uma Sinha
Filed: 28 Jul 21
Utility
Cerdulatinib for the Treatment of B-cell Malignancies
31 Mar 22
Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof.
Anjali Pandey, Gregory Coffey, Janet Leeds
Filed: 10 May 21
Utility
Methods for Preparing Ammonium Tetrathiomolybdate
17 Mar 22
This disclosure relates to crystalline ammonium tetrathiomolybdate having pharmaceutical grade purity and processes for manufacturing crystalline ammonium tetrathiomolybdate.
Viveca Oltner, Niklas Wahlstrom
Filed: 14 Jan 20
Utility
Fusion Proteins and Methods of Treating Complement Dysregulation Using the Same
13 Jan 22
Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain.
Julian Chandler, Christian Cobaugh, Keith Bouchard, Jeffrey Hunter
Filed: 22 Aug 19
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis In Pediatric Patients
6 Jan 22
The disclosure provides methods of treating myasthenia gravis (MG) in a pediatric subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (CS).
Róisín ARMSTRONG, Kenji FUJITA
Filed: 19 Nov 19
Utility
Subcutaneous Dosage and Administration of ANTI-C5 Antibodies for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
23 Dec 21
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).
Lori Volles, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Xiang Gao
Filed: 30 Oct 19
Utility
Co-administration of a Hyaluronidase and ANTI-C5 Antibody for Treatment of Complement-associated Conditions
16 Dec 21
Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
Andrew Denker, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Yang Dai, Xiang Gao
Filed: 30 Oct 19
Utility
Inhibition of Tissue Factor Pathway Inhibitor with Factor Xa Derivatives
9 Dec 21
The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
Filed: 16 Feb 21
Utility
Antidotes to Factor Xa Inhibitors
2 Dec 21
The present disclosure relates to antidotes to anticoagulants targeting factor Xa.
Pamela B. Conley, Genmin Lu, Leonard G. Presta, John T. Curnutte
Filed: 18 Jun 19
Utility
Preparation of Factor Xa Derivatives
11 Nov 21
The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product.
Mark Karbarz, Pamela B. Conley, Genmin Lu
Filed: 9 Mar 21
Utility
Antidotes for Factor Xa Inhibitors and Methods of Using the Same
4 Nov 21
The present invention relates antidotes to anticoagulants targeting factor Xa.
Uma Sinha, Genmin Lu, Pamela B. Conley
Filed: 9 Mar 21
Utility
DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
28 Oct 21
Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof, in pediatric patients.
Lori PAYTON, Andrew DENKER, Eugene Scott SWENSON, Rajendra PRADHAN, Stephan ORTIZ, Marc VALLEE, Christian MIX, Xiang GAO
Filed: 29 May 19
Utility
Manufacturing of Glycoproteins
14 Oct 21
A method of producing recombinant alkaline phosphatase comprising control of production parameters, particularly harvest clarified culture fluid (HCCF) and filtration pool (UFDF), to provide a defined total sialic acid content.
Rahul GODAWAT, Meghan DEWITT, Siguang SUI, Saravanamoorthy RAJENDRAN
Filed: 13 Mar 19
Utility
Lyophilized Formulations for Factor Xa Antidote
16 Sep 21
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes.
Juan Wang, Gregory A. Sacha, Phuong M. Nguyen
Filed: 28 May 21
Utility
Atypical Hemolytic Uremic Syndrome (Ahus) Biomarker Proteins
16 Sep 21
The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor.
Susan Faas MCKNIGHT, Roxanne COFIELL, Anjli KUKREJA, Krystin A. BEDARD, Yan YAN
Filed: 29 Jan 21
Utility
Antibody Immune Cell Inhibitor Fusion Proteins
26 Aug 21
The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an immune effector cell when bound to a target antigen.
Julian Chandler
Filed: 23 Apr 18
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis
12 Aug 21
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Camille Bedrosian, Fanny O'Brien, Jing Jing Wang
Filed: 15 Jan 21
Utility
Humanized ANTI-CD200 Antibodies and Uses Thereof
29 Jul 21
Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200.
Taneisha Ann-Tanara MACK, Douglas L. SHERIDAN, Tadas PANAVAS
Filed: 20 Dec 18